MGC Pharmaceuticals submits patent application for CimetrA to European IP Office

MGC Pharmaceuticals Ltd (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) has submitted a patent application for CimetrA^TM, the Investigational Medicinal Product (IMP) assigned to the company, to the Slovenian Intellectual Property Office (SIPO).

The company submitted its patent application that was accepted by SIPO on May 5, 2021, the priority date for the patent.

CimetrA^TM has been designed for multiple therapeutic applications including acute and chronic inflammation, COVID-19 and variants of influenza, autoimmune diseases, adverse events resulting from the various forms of cancer therapy, and the promotion of an immune response to bacterial, viral, fungal and parasitic infection – highlighting its versatility as a medicine.

This initial patent application gives MGC Pharma priority to file subsequent patent applications for CimetrA^TM in other jurisdictions and other IP agencies.

“Bringing to market in multiple jurisdictions”

MGC Pharma expects the patent to be issued within the next 12 months.

MGC Pharma co-founder and managing director Roby Zomer said: “We are delighted that the SIPO recognises the unique formulation of CimetrA^TM, something we believe will be transformational in the treatment of COVID-19 as well as numerous other conditions.

“The submission of this patent application is an important next step in bringing CimetrA^TM to market in multiple jurisdictions and ultimately treating people and patients on a global scale whilst Phase III trials for the IMP continue.”

The company continues to progress towards the commencement of its phase III clinical trial for CimetrA^TM in order to demonstrate the full efficacy and pharmacokinetic profile of the treatment in different variants of the COVID-19 virus.

Novel pharmaceutical composition

The patent provides a nano-micellular pharmaceutical synergetic composition consisting of Curcumin, Boswellia, Artemisinin, and optionally Cannabinoids and/or Nitroxides.

This composition can be manufactured in liquids or in solid pharmaceutically acceptable carriers, has antioxidant, anti-inflammatory, immuno-modulating, anti-viral and anti-cancer properties and can be designed for multiple therapeutic applications, utilising self-nanoemulsifying drug delivery systems (SNEDDS).

The patent sets out the specific antioxidant, anti-inflammatory, immune-modulating, anti-viral, and anti-cancer properties of CimetrA^TM, designed for multiple therapeutic applications including the treatment of chronic inflammation, severe acute respiratory syndrome coronavirus (SARS-Covid, COVID-19) and heavy variants of influenza, as well as various types of cancer.

This is in addition to its efficacy in relation to the regulation of the human body’s circadian rhythm and homeostasis which promotes an immune response to bacterial, viral, fungal and parasitic infections.

COVID-19 applications

Preclinical and clinical results to date support the pharmaceutical composition of CimetrA^TM as an effective treatment for addressing anti-inflammation and cytokine over-production (known as cytokine storm) in all tested COVID-19 patients.

Many plant molecules which make up the API are hydrophobic (not water soluble) and thus cannot be readily absorbed by the body.

Once these are encapsulated within the oil-free type IV nano-micellar SNEDDS, the bioavailability of the molecules is increased and the API are emulsified and absorbed more efficiently, resulting in more effective treatment.

The submission of this patent, therefore, has significant implications for the pharmaceutical industry and will ultimately help to increase general drug efficiency.

Story by ProactiveInvestors